Navigation Links
Simeprevir Data in Hepatitis C Patients to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Date:10/1/2013

meprevir
Simeprevir is an investigational NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease, including all stages of liver fibrosis. Simeprevir works by blocking the protease enzyme that enables the hepatitis C virus to replicate in host cells.

Janssen is responsible for the global clinical development of simeprevir and has acquired exclusive, worldwide marketing rights, except for in the Nordic countries. Medivir will retain marketing rights for simeprevir in these countries. A Marketing Authorisation Application was submitted to the European Medicines Agency (EMA) in April seeking approval of simeprevir for the treatment of genotype 1 or genotype 4 chronic hepatitis C. To date, more than 3,700 patients have been treated with simeprevir in clinical trials.

Additionally, simeprevir is being studied in combination with several direct-acting antiviral agents (DAAs) with different mechanisms of action, with and without ribavirin, as part of interferon-free regimens. These include:

  • The Phase 2 COSMOS study of simeprevir and Gilead's nucleotide polymerase inhibitor sofosbuvir (GS-7977) in treatment-naive and previous null-responder genotype 1 HCV patients, including patients with cirrhosis; 
  • A Phase 2 study of simeprevir and Bristol-Myers Squibb's NS5A replication complex inhibitor daclatasvir in treatment-naive and previous null-responder genotype 1 HCV patients; 
  • The Phase 2 HELIX-1 study of simeprevir and Idenix's once-daily pan-genotypic NS5A inhibitor samatasvir (IDX719) in treatment-naive genotype 1b and genotype 4 HCV patients.

For additional information about simeprevir, please visit www.clinicaltrials.gov.

About Hepatitis C
Hepatitis C, a blood-borne in
'/>"/>

SOURCE Janssen R&D Ireland
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
2. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
3. Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
4. Findings from Two Phase 3 Studies of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
5. Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
6. U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C
7. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
8. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
9. Aethlon Medical Reports Undetectable Hepatitis C Virus (HCV) in Genotype 1, Genotype 3, and Genotype 5 Patients Treated with Hemopurifier® Therapy
10. Bulgaria Launches Development of National Hepatitis Plan
11. Major Breakthrough in Hepatitis C Vaccine Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Ore. , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s ... a targeting guide with accompanying instrumentation to place and ... adjunct to the soft tissue (e.g. ligament) repair or ... tissue repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
(Date:1/14/2014)... 2014 NineSigma , Inc., the leading innovation ... Leadership Summit , May 14-16, 2014 at the Global ... . This is the premier ... breakthrough achievements through open innovation. Participants will learn how ...
(Date:1/14/2014)... 14, 2014   Evidera , a leading provider of ... Center for Drug Evaluation and Research (CDER), U.S. Food ... guidance document for a patient-reported outcome (PRO) measure in ... Disease Tool [EXACT] for Measurement of Symptoms of Acute ...
Breaking Medicine Technology:Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 3Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 4
... Medarex, Inc. (Nasdaq:, MEDX ) announced today ... non-fucosylated version of MDX-060 that targets CD30, a,marker ... malignant cells of,Hodgkin,s lymphoma (HL) as well as ... potency and efficacy in cell lines when,compared to ...
... TEL AVIV, Israel, December 8 InspireMD, Ltd. announced,that ... use in Israel,by the Israeli Ministry of Health. , ... system presents a novel combination of a coronary,stent merged ... by an expandable, flexible fishnet style, micron level knit,sleeve ...
Cached Medicine Technology:Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma 2Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma 3MGuard(TM) Coronary Stent System Approved in Israel 2MGuard(TM) Coronary Stent System Approved in Israel 3
(Date:4/17/2014)... most popular vaccine brands for children may not be ... some cost factors when choosing vaccines, driving the market ... to a new study by University of Illinois researchers. ... driven by numerous factors," says Sheldon H. Jacobson, a ... science and of mathematics at the U. of I. ...
(Date:4/17/2014)... the University of California, San Diego School of Medicine ... have suffered a recent major loss are more likely ... , The study is published in this month,s issue ... , Because compassionate behaviors are associated with better health ... insights into ways to improve the outcomes of individuals ...
(Date:4/17/2014)... MD, was recently invited to submit a review ... Microbiology , one of the world,s foremost scientific ... specialist, and chair of the Department of Pediatrics ... analyzed the epidemiology and microbiology of co-infections during ... as more recent 2009 novel H1N1 pandemic. ...
(Date:4/17/2014)... MAYWOOD, Il. (April 17, 2014) Doctors who ... disease called lymphangioleiomyomatosis (LAM) can face an agonizing ... progression of the disease and help relieve shortness ... lung transplants, and sirolimus can cause potentially fatal ... said pulmonologist Dr. Daniel Dilling, medical director of ...
(Date:4/17/2014)... about one in five infants in the United States ... first several months after birth. Research into probiotic use ... the April 1, 2014 issue of the British ... study, "Probiotics and Infant Colic," concluding that the use ... colic did not reduce crying or fussing in ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... the reason why isolated women are less vulnerable to falling ill ... ,The study is an eye-opener to the upcoming proof that ... a clue to the reason why socially isolated men are prone ... have shown a connection between stress and immune function. But this ...
... Bachoud-Lévi, M.D., and colleagues of the French national institute ... Huntington's disease// who previously received intracerebral fetal neural grafts ... ,But the same investigators reported today that ... years and then began to decline over the next ...
... at University of California have gained valuable insights about ... , a finding that may eventually accelerate current research ... is a joint effort by Dr. Frank Sauer (UCR ... Munich) and other researchers from University of California. The ...
... School of Public Health are one of the 14 ... Environmental Health Sciences// (NIEHS) to study the association between ... is a new study to control the rising obesity ... an individual’s body size. Working with various city departments, ...
... Research Institutes, Inc (NDRI) in New York City ... the role// of social supports, spirituality, religiousness, life ... recovery from addiction. The study reveals markedly improved ... a decrease in stress when people were inclined ...
... fear regarding the elevated risk of lymphoma associated with ... has found that such treatments may not confer an ... be seen in the latest issue of Arthritis & ... been found to increase with worsening of the chronic ...
Cached Medicine News:Health News:Women Portray Stronger Immune Response As Compared to Men, Study Suggests 2Health News:Fetal Neural Grafts Improves Motor and Cognitive Function in Huntington Patients 2Health News:Drug Addiction Recovery Buffered by Spirituality 2Health News:No Lymphoma Risk From Rheumatoid Arthritis Drugs 2
Flattened points in vertical plane, straight shafts, cross action, round handle....
... cross action. Round handle. Divides nucleus for ... Nuclei of any hardness can be pre-chopped ... of pre-chopped nuclear fragments is rapid. Risk ... diminished. Shortened ultra sound time and minimal ...
1.5 mm inner cutting edge....
Nucleus chopper....
Medicine Products: